Creating antibodies to study long-COVID in hamsters
Official title: Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)
Funded at Qoolabs, INC. · NIH-10933277 · Data updated 2026-11-12
This study is looking to create special antibodies that can help researchers learn more about how the immune system responds to long-COVID in hamsters, which could eventually help us understand the condition better for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Qoolabs, INC. NIH-funded |
| Lab location | 1 site (Carlsbad, UNITED STATES) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $600,000 |
| NIH project number | 75N93023C00035-0-9999-1 |
| Project ID | NIH-10933277 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals experiencing long-COVID symptoms and those interested in the underlying immune mechanisms.
✕Less likely to help
Patients who do not have long-COVID or are not affected by SARS-CoV-2 may not receive any benefit from this research.
What this research studies
This research focuses on developing high-affinity monoclonal antibodies targeting specific immune cells in Syrian golden hamsters, which are important for understanding long-COVID. The approach involves immunizing rabbits with specially designed proteins to produce these antibodies. Once generated, the antibodies will be validated for their effectiveness in studying long-COVID in hamster models infected with SARS-CoV-2. This work aims to enhance our understanding of the immune response related to long-COVID.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and treatments for long-COVID by providing insights into immune responses.
How similar studies have gone: Other research has shown promise in using monoclonal antibodies for studying immune responses, indicating that this approach could be effective.
Where this research is happening
-
Qoolabs, INC.
Carlsbad, United States Active
Researchers
- Principal investigator: Qi, Hong — Qoolabs, INC.
- Study coordinator: Qi, Hong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD8 T cells respond to SARS-CoV-2 and their role in Long COVID
This study is looking at how certain immune cells called CD8 T cells work to fight off COVID-19, especially in people who have lingering symptoms, to help find ways to improve vaccines and treatments for the virus and its long-term effects.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.